Science, Research & Publications
HOT OFF THE PRESS – SITC’S NEW CANCER IMMUNOTHERAPY TEXTBOOK!
SITC is delighted to announce the launch of its new textbook, Cancer Immunotherapy Principles and Practice. Edited by Drs. Lisa H. Butterfield, Howard L. Kaufman and Francesco M. Marincola, the book features five sections and over 50 chapters authored by leading authorities in the field. Serving as a comprehensive resource for oncologists, fellows, immunologists, cancer researchers and any healthcare practitioner seeking to understand the basic science and clinical application of cancer immunotherapy, Cancer Immunotherapy Principles and Practice makes a challenging and dynamic subject understandable. SITC members are eligible to receive up to a 25 percent discount and free shipping. Login to your SITC CONNECT account for more details including the promo code, or stop by SITC’s exhibit booth #2015 while in Chicago.
Experience more on SITC CONNECT! Save a reminder of this textbook launch by adding it directly to your calendar on a desktop computer or mobile device.
SITC IMMUNE BIOMARKERS TASK FORCE RECOMMENDATIONS PUBLISHED IN JITC
New in this month’s Journal for ImmunoTherapy of Cancer (JITC), SITC Immune Biomarkers Task Force Working Group 4 published their recommendations on predicting clinical outcomes using baseline measures. This publication emphasizes the need for a comprehensive understanding of baseline immunity in the periphery, and the tumor microenvironment, to drive biomarker identification, and elucidate why response to cancer immunotherapy is limited to a subset of patients. Click here to read, “Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.”
Did you know? JITC’s article processing charges are waived for SITC members through 2017 – an incredible $2,500 value! Join SITC, renew your membership, or check your current membership status.
SITC JOINS THE FNIH BIOMARKERS CONSORTIUM AS A MEMBER
SITC has become the newest member of the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium (BC). This public-private biomedical research partnership, managed by the FNIH, brings together the expertise and resources needed to rapidly identify, develop and qualify potential high-impact biomarkers to enable improvements in drug development and regulatory decision-making. The BC conducts projects in four main areas: Cancer, Immunity & Inflammation, Metabolic Disorders and Neuroscience. As a member, SITC will contribute scientific and technical expertise to emerging and existing projects in cancer immunotherapy. Working with more than 30 other member organizations, the society will help create a new era of precision medicine with therapies that are better tailored for patients.
NCI FORMULARY – EXPEDITING ACCESS TO CANCER DRUGS FOR CLINICAL TRIALS
The National Cancer Institute (NCI) agent formulary, launched in January 2017, is a public-private partnership between the NCI and pharmaceutical and biotech companies that provides academic investigators with rapid access to pharmaceutical agents for use in cancer clinical trials. Within this program, pharmaceutical company collaborators provide investigators at NCI-designated Cancer Centers with proprietary agents for use in trials supported by the NCI Formulary. With a particular focus on drugs that target molecular pathways under investigation by multiple pharmaceutical collaborators, the NCI Formulary facilitates conduct of clinical trials by streamlining clinical trial approval, distribution of pharmaceutical agents, and reporting of trial efficacy and safety data. It is hoped that, in this way, the NCI Formulary will accelerate delivery of new treatments to patients with cancer. For more information, see NCI Formulary and lists of agents.